Express News | Nurix Therapeutics Says David Lacey Steps Down From Chair Role And Will Remain Board Member And Retain Committee Leadership Roles; Current Board Member Julia Gregory Elected New Board Chair
Express News | Nurix Therapeutics Inc: David L. Lacey Steps Down From Chair Role and Will Remain Board Member and Retain Committee Leadership Roles
Express News | Nurix Therapeutics Inc: Current Board Member Julia P. Gregory Unanimously Elected New Board Chair
Express News | Nurix Therapeutics Announces Board Chair Transition
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948
Nurix Therapeutics Is Maintained at Buy by Stifel
Nurix Therapeutics Is Maintained at Buy by Stifel
Express News | Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target
Express News | Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Express News | Nurix Therapeutics Announces Upcoming Oral Presentation of New Data From Ongoing Clinical Trial of Nx-5948, a Selective Bruton’s Tyrosine Kinase (Btk) Degrader, at the European Hematology Association Congress (Eha2024)
Express News | Nurix Therapeutics Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $20
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Express News | Stephens & Co. Initiates Coverage On Nurix Therapeutics With Overweight Rating, Announces Price Target of $20
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 42.76% Stephens & Co. → $20 Initiates Coverage On → Overweight 04/11/2024 64.17% RBC Capital $2
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat
Nurix Therapeutics(NRIX.US) Officer Sells US$44,878.17 in Common Stock
$Nurix Therapeutics(NRIX.US)$ Officer van Houte Hans sold 3,499 shares of common stock on May 2, 2024 at an average price of $12.826 for a total value of $44,878.17.Source: Announcement What is statem
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Nurix Therapeutics (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Nurix Therapeutics (NASDAQ:NRIX) Climbs Higher After Beating Expectations